Rcnet 12.5mg Capsule contains the active ingredient Sunitinib and is classified as a tyrosine kinase inhibitor. It works by blocking enzymes called tyrosine kinases that are involved in the growth and spread of cancer cells. Common Rcnet 12.5mg uses include the treatment of gastrointestinal stromal tumors (GIST), a rare cancer that can start anywhere in the gastrointestinal tract. Doctors may also prescribe Rcnet 12.5mg for kidney cancer and pancreatic neuroendocrine tumors (PNET). The appropriate Rcnet 12.5mg dosage for GIST is determined by the physician based on the patient’s condition and response to treatment. Cancer is a disorder in which abnormal cells grow in an uncontrolled manner. This medication is not recommended for individuals under 18 years of age.

Patients often check the Rcnet 12.5mg capsule price or Rcnet 12.5mg BDR Pharma price, which may vary depending on the pharmacy and location. Some may consider the option to Buy Rcnet 12.5mg online, but it should only be purchased with a valid prescription. Avoid confusion with strengths like Rcnet 12.5mg capsule 1mg, and always follow the prescribed dosage.

Like other anticancer medicines, it may cause Rcnet 12.5mg side effects such as fatigue, diarrhea, high blood pressure, skin discoloration, and mouth sores. In some cases, doctors may recommend Rcnet 12.5mg substitutes depending on the patient’s condition and tolerance.

Before taking Rcnet 12.5mg Capsule, it is important to inform your doctor if you have blood conditions, heart problems, liver disorders, kidney problems, skin disorders, diabetes, seizures, or thyroid disorders. Also, inform your doctor if you have recently had surgery or are planning to undergo surgery. Tell your doctor if you have hypertension, as this medication may increase blood pressure as a side effect. Avoid consuming grapefruit in any form during treatment. Check with your dentist if you have any oral problems such as mouth pain, swelling, or sores before starting treatment.

Rcnet 12.5mg Capsule is used in the treatment of the following condition: 

• Renal cell carcinoma (RCC)

• Gastrointestinal stromal tumors (GIST)

• Pancreatic neuroendocrine tumors (PNET)

• Medullary thyroid cancer

• Certain kidney cancer

The therapeutic effects of Rcnet 12.5mg Capsule include slowing down or stopping the growth and spread of cancer cells in the body, thereby reducing the size and number of tumors. It works by inhibiting the activity of specific proteins known as tyrosine kinases, which are involved in the signaling pathways that control cell growth and division. It can help to prevent cancer cells from growing and spreading by blocking these pathways.

1. CYP3A4 Inhibitors (e.g., ketoconazole, erythromycin, clarithromycin)
   May increase the levels of Rcnet 12.5mg Capsule in the body, leading to higher risk of side effects.

2. CYP3A4 Inducers (e.g., rifampicin, phenytoin, carbamazepine)
   Can reduce the effectiveness of the medication by lowering its concentration in the blood.

3. Antihypertensive Drugs (e.g., amlodipine, enalapril)
   May require dose adjustments as this medication can increase blood pressure.

4. Anticoagulants (e.g., warfarin)
   May increase the risk of bleeding when used together.

5. Other Anticancer Drugs (e.g., doxorubicin)
   Can enhance toxicity and increase side effects such as fatigue and low blood counts.

6. Thyroid Medications (e.g., levothyroxine)
   May require monitoring as this drug can affect thyroid function.

7. Herbal Supplements (e.g., St. John’s Wort)
   Can reduce the effectiveness of the medicine by altering drug metabolism.

8. Grapefruit or Grapefruit Juice
   Should be avoided as it may increase drug levels and side effects

• Rcnet 12.5mg Capsule should be stored at room temperature, between 68°F and 77°F (20°C and 25°C).

• Keep it in the original package.

• Protected from moisture, light, and heat.

• Keep it out of reach from children and pets.

Rcnet 12.5mg Capsule is taken orally, in the form of capsules, with a glass of water. The capsules should be swallowed whole and not crushed, chewed, or opened. The recommended dose may vary depending on the type of cancer being treated, the patient's age and weight, and other factors. This medication is usually taken once a day, with or without food, at around the same time each day. If you miss a dose then do not double the dose to compensate for the missed dose.

Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. Side effects related to Rcnet 12.5mg Capsule are as follows:

Serious:

• Heart failure or heart attack

• Elevated liver function tests.

• Liver failure

• Proteinuria

• Acute kidney injury

• Interstitial lung disease (inflammation of lung walls)

• Pulmonary arterial hypertension

• Gastrointestinal perforation or fistula

• Haemorrhage (bleeding)

• Hypothyroidism (low thyroid function)

• Hypoglycemia (low blood sugar)

Common 

• Fatigue

• Nausea and vomiting

• Diarrhoea

• Loss of appetite

• Hand-foot syndrome

• Skin discoloration or rash

• High blood pressure

• Headache

• Hair loss

• Changes in taste

• Dry skin or itching

• Nosebleeds

1. Follow your healthcare provider’s instructions carefully while taking Rcnet 12.5mg Capsule.

2. Do not change the dose or stop the medication without consulting your doctor.

3. Avoid consuming grapefruit or grapefruit juice during treatment.

4. Grapefruit may increase the medication levels in the blood and raise the risk of side effects.

5. Use a reliable method of birth control during treatment.

6. Continue contraception for at least four weeks after the last dose.

7. Be aware that this medication may cause serious side effects.

8. Stay alert to any symptoms or changes in your health.

9. Report any unusual signs or symptoms to your doctor immediately, even if they seem minor.

10. Regular monitoring and proper precautions can help ensure safe and effective treatment.

1. Pfizer, U.S Drug and food safety administration (FDA), [Revised on Dec 2018], [Accessed on 5th April 2023], 
   https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021938s035lbl.pdf
2. Anton Wellstein, Giuseppe Giaccone, Michael B. Atkins, and Edward A. Sausville, Pathway-Targeted Therapies: Monoclonal Antibodies, Protein Kinase Inhibitors, and Various Small Molecules, Goodman & Gilman’s Pharmacological Basis of Therapeutics, 13th Edition, 2018, 1203-1236.
3. Robert J. Thomson; Majid Moshirfar; Yasmyne Ronquillo, Tyrosine Kinase Inhibitors, [Revised on 21st Jan 2021] [Accessed on 5th April 2023],  
   https://www.ncbi.nlm.nih.gov/books/NBK563322/
4. Pfizer, Electronic Medicines Compendium (EMC) [Revised on Mar 2021] [Accessed on 5th April 2023],  https://www.medicines.org.uk/emc/files/pil.7966.pdf
5. KD Tripathi, Anticancer Drugs, Essentials of Medical Pharmacology, 8th Edition, 2019, 915-936.